Protalix BioTherapeutics, Inc. (PLX) - Latest Market Data

Price & Market Data

Price: $2.10

Daily Change: +$0.07 / 3.33%

Daily Range: $2.03 - $2.12

Market Cap: $169,200,432

Daily Volume: 708,286

Performance Metrics

1 Week: 4.75%

1 Month: -5.63%

3 Months: -33.49%

6 Months: 22.51%

1 Year: 23.24%

YTD: 14.48%

About Protalix BioTherapeutics, Inc. (PLX)

Essential market overview for Protalix BioTherapeutics, Inc. (PLX). Current price: 2.10, daily change: +$0.07 / 3.33%. Market cap: 169,200,432. All key performance metrics for a full analysis.

Company Details

Employees: 226

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Selected stocks

Texxon Holding Limited (NPT)

OFS Credit Company, Inc. (OCCI)

Cre8 Enterprise Limited (CRE)

Iveda Solutions, Inc. (IVDA)

Aclaris Therapeutics, Inc. (ACRS)